ISSN: 1948-5956
Journal of Cancer Science & Therapy
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

The Regucalcin Gene is a Key in the Therapy of Hepatocellular Carcinoma

Masayoshi Yamaguchi*
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, USA
Corresponding Author : Masayoshi Yamaguchi, PhD
Department of Hematology and Medical Oncology
Emory University School of Medicine
1365 C Clifton Road, NE, Atlanta, GA 30322, USA
E-mail: yamamasa1155@yahoo.co.jp
Received January 20, 2014; Accepted January 23, 2014; Published January 27, 2014
Citation: Yamaguchi M (2014) The Regucalcin Gene is a Key in the Therapy of Hepatocellular Carcinoma. J Cancer Sci Ther 6:e132. doi:10.4172/1948-5956.1000e132
Copyright: © 2014 Yamaguchi M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google

Visit for more related articles at Journal of Cancer Science & Therapy

Hepatocellular carcinoma (HCC), the most common primary liver cancer, is one of the most prevalent malignant diseases worldwide, and the third most common causes of cancer-related death [1-3]. Globally, there are approximately 750,000 new cases of HCC reported per year. The incidence of HCC is increasingly in the United States and other developed countries. Moreover, features of HCC are an aggressive cancer with a dismal outcome largely due to metastasis and postsurgical recurrence. In most cases, HCC originates on a background of cirrhosis, a chronic and diffuse hepatic disease that result from continuous liver injury and regeneration [3]. Cirrhosis is present in approximately 80%- 90% of HCC patients and constitutes the largest single risk factor. In cirrhotic liver, changes in fat metabolism associated with the activation of adipocyte-like pathways are thought to be involved in neoplastic transformation [3]. Increased hepatocyte turnover, inflammation, and oxidative DNA damage is implicated in the pathogenesis of the liver disease including obesity, Type 2 diabetes, insulin resistant, and nonalcoholic fatty liver disease. The prevalent risk factors for HCC are also the cause of liver cirrhosis, and include viral infections (hepatitis B and C) and alcohol consumption; further risk factors include tobacco smoking, exposure to aflatoxin B1 and vinyl chloride, diabetes, and genetic disorders, such as hemochromatosis and alpha-1 antitrypsin deficiency [4-8].
Hepatocarcinogenesis is a multistep process initiated by external stimuli that lead to genetic changes in hepatocytes or stem cells, resulting in proliferation, apoptosis, dysplasia and neoplasia. The majority of HCC cases are also related to chronic viral infections. Hepatitis B virus (HBV) DNA integrates into the host genome, inducing chromosome instability and insertional mutations that may activate various oncogenes, such as cyclin A [9-12]. Viral proteins, in particular X protein (HBx), act as transactivators to upregulate several oncogenes (such as c-myc and c-jun) and transcriptional factors (such as nuclear factor-κB) [13-15]. Additionally, HBx activates promoters of genes encoding interleukin-8 (IL-8), tumor necrosis factor (TNF), transforming growth factor (TGF)-β and epidermal growth factor receptor (EGFR) [16]. HBx can also stimulate several signal transduction pathways, including the JAK/STAT, RAS/RAF/MAPK, and Wnt/β-catenin pathways [16,17]. The contributions of hepatitis C virus (HCV) to hepatocarcinogenesis are mediated through viral proteins, including core, NS3 and NS5A proteins. HCV core protein can promote apoptosis or cell proliferation through interaction with p53 or upregulation of Wnt-1 at the transcriptional level [18-20].
The prognosis of advanced HCC remains poor in spite of the development of novel therapeutic strategies [21]. Traditional therapies are not effective for HCC and are too toxic for patients with cirrhosis. Transarterial chemoembolization and radioembolization are the main treatments for intermediate-stage HCC at the present time. Improved knowledge of the oncogenic processes and signaling pathways that regulate tumor cell proliferation, differentiation, angiogenesis, invasion and metastatis has led to the identification of several potential therapeutic targets, which have driven the development of molecularly targeted therapies [21]. An ideal cancer target meets the following criteria: the target is relatively specific for cancer cells (not expressed or expressed at very low levels in normal cells but overexpressed in cancer cells) [21]. Meanwhile, overexpression of the target is associated with malignant biological phenotypes and/or poor prognosis; the target plays an essential role in cancer initiation and progression, and inhibition of expression or activity of the target induces growth suppression and/or apoptosis in cancer cells. The target is “drugable” as an enzyme (e.g., a kinase) or cell surface molecule (e.g., a membrane-bound receptor) that can be easily screened for small-molecule inhibitors or targeted by a specific antibody [21,22]. The only systemic therapy available for advanced HCC is based on the multikinase inhibitor sorafenib [22], which is the most effective therapeutic tool for advanced nonresectable HCC, in which it can slightly improve patient survival. The survival of patients with advanced HCC treated with sorafenib depends on the absence of liver dysfunction and on the status of the patient [23]. In the past few years, the use of sorafenib in combination with transarterial chemoembolization has improved survival rates in patients with advanced HCC. Recently, new perspectives in cancer treatment have appeared with the advent of microRNAs, a novel class of noncoding small RNAs [24].
Regucalcin, which the author discovered in 1978 [25-28], may play a pivotal role in the suppression of hepatocarcinogenesis [29-31]. Regucalcin plays a role as a suppressor protein in various cell signal transductions [26-28]. The regucalcin gene is located on the X chromosome in consisting of seven exons and six introns [32]. Regucalcin (RGN) and its gene (rgn) are identified in over 15 species consisting of regucalcin family and the gene species are highly conserved in vertebrate species [32]. The regucalcin gene expression is regulated through various transcription factors (including AP-1, NF1-A1, RGPR-p117, β-catenin, SP1 and others), which are identified as the enhancer and suppressor, and this expression is regulated with hormonal stimulation and physiological state [32]. Regucalcin plays a pivotal role as a suppressor protein in various signal transductions to maintain cell homeostasis for stimuli, and it plays a multifunctional role in cell regulation through maintaining of intracellular Ca2+ homeostasis and suppressing of signal transduction in various cell types [26-28]. Interestingly, the cytoplasmic regucalcin is translocated into the nucleus and inhibits nuclear Ca2+-dependent and -independent protein kinases and protein phosphatases, Ca2+-activated endonuclease, and DNA and RNA synthesis [33].
Regucalcin has been demonstrated to play a role as a suppressor protein in cell proliferation, which is mediated through various signaling stimulations, in the cloned normal rat kidney proximal tubular epithelial NRK52E cells and the cloned rat hepatoma H4-II-E cells [31,34,35]. Regucalcin causes G1 and G2/M phase cell cycle arrest in these cells [31,36]. The anti-cell proliferation effect of regucalcin is not dependent on apoptosis; regucalcin suppresses apoptosis induced through multisignaling pathway [37]. Molecular mechanisms by which regucalcin suppresses the promotion of cell proliferation have been elucidated. Regucalcin, which is expressed through signaling factors that stimulate cell proliferation, is translocated into the nucleus with mechanism by which is mediated through protein kinase C-dependent signaling [31,34]. Regucalcin directly inhibits the activities of various Ca2+/calmodulin-dependent enzymes, protein kinases and protein phosphatases in the cytoplasm and nuclei [27,28,31]. Regucalcin inhibits nuclear DNA and RNA synthesis, and it has suppressive effects on the expression of c-myc, Ha-ras, and c-src mRN, which are tumorstimulator genes and also stimulates the expression of p53 and Rb mRNAs that are tumor-suppressor genes [31,38]. Moreover, regucalcin inhibits protein synthesis and stimulates protein degradation due to inhibiting aminoacyl-tRNA synthetase and activating cysteinyl protease [27,28]. Thus, suppressive effects of regucalcin on cell proliferation are mediated through the suppression of many cell signaling processes including the suppression of oncogene expression and stimulation of tumor suppressor gene expression in liver cells [31,33,38].
Noticeably, the regucalcin gene and its protein levels have been found to specifically suppress in human hepatocellular carcinoma (HCC) using analysis with multiple gene expression profiles and proteomics [39-43]. The suppression of regucalcin gene expression has been shown to occur at earlier periods of carcinogenesis in rats treated with diethylnitrosamine and then 2-acetylaminofluorene combined with partial hepatectomy, which induces an increase in proliferating cells [29]. The suppression of regucalcin protein expression has also been identified in proteomic analysis that was differentially expressed in the livers of rats fed 5% ethanol for 1 and 3 months [30]. In addition, regucalcin mRNA expression is suppressed by disorder of liver metabolism (including carbon tetrachloride [44], galactosamine [45] and phenobarbital [46] administration, the conditions of diabetes and ethanol ingestion [47]), which may lead to cirrhosis and HCC. The suppression of regucalcin gene expression may lead to the development of HCC.
Regucalcin, a suppressor protein in cell signaling system, may play a role as a key molecule in the depression of cell proliferation and carcinogenesis of various tissues and cell types. Overexpression of regucalcin in cancer cells may play preventive and therapeutic roles in carcinogenesis. The development of a novel gene therapy with the regucalcin gene deliver system will be expected in clinical aspects.
Acknowledgements
Regucalcin studies of the author were supported by a Grant-in-Aid for Scientific Research (C) No.63571053, No.02671006, No.04671362, No.06672193, No.08672522, No.10672048, No.13672292 and No.17590063 from the Ministry of Education, Science, Sports, and Culture, Japan. Also, the author (MY) was awarded the Bounty of Encouragement Foundation in Pharmaceutical Research, Japan and the Bounty of the Yamanouchi Foundation for Research on Metabolic Disorders, Japan. This study was also supported by the Foundation for Biomedical Research on Regucalcin.
References















































 
Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11246
  • [From(publication date):
    March-2014 - Jul 31, 2016]
  • Breakdown by view type
  • HTML page views : 7517
  • PDF downloads :3729
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version